Your browser doesn't support javascript.
loading
Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine Receptor.
Free, R Benjamin; Cuoco, Caroline A; Xie, Bing; Namkung, Yoon; Prabhu, Varun V; Willette, Blair K A; Day, Marilyn M; Sanchez-Soto, Marta; Lane, J Robert; Laporte, Stéphane A; Shi, Lei; Allen, Joshua E; Sibley, David R.
Afiliação
  • Free RB; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
  • Cuoco CA; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
  • Xie B; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
  • Namkung Y; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
  • Prabhu VV; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
  • Willette BKA; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
  • Day MM; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
  • Sanchez-Soto M; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
  • Lane JR; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
  • Laporte SA; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
  • Shi L; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
  • Allen JE; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
  • Sibley DR; Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (R.B.F., C.A.C., B.K.A.W., M.M.D., M.S-S., D.R.S.); Chimerix, Inc., Durham, North Carolina (V.V.P., J.E.A.); Computational Chemistry and Molecular Biophysics
Mol Pharmacol ; 100(4): 372-387, 2021 10.
Article em En | MEDLINE | ID: mdl-34353882
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Piridinas / Pirimidinas / Receptores de Dopamina D2 / Antagonistas dos Receptores de Dopamina D2 / Imidazóis / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Mol Pharmacol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Piridinas / Pirimidinas / Receptores de Dopamina D2 / Antagonistas dos Receptores de Dopamina D2 / Imidazóis / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Mol Pharmacol Ano de publicação: 2021 Tipo de documento: Article